Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.53 |
| ▸ | RELA | Q04206 | 1/20 | 0.53 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.52 |
| ▸ | TUBB | P07437 | 2/20 | 0.52 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.52 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.52 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.52 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.52 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.52 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.52 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.52 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.52 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31275137 | 0.92 | CYP19A1 (0.74) | CYP19A1MEN1KMT2AMAPTGAA | |
| SCHEMBL17536647 | 0.92 | CYP19A1 (0.74) | CYP19A1MEN1KMT2AMAPTGAA | |
| SCHEMBL16263998 | 0.86 | KMT2A (0.54) | CYP19A1MEN1KMT2AMAPTGAA | |
| SCHEMBL17547636 | 0.85 | SLC5A1 (0.58) | CYP19A1MAPTGAANFKB1NFKB2 | |
| SCHEMBL17536648 | 0.85 | CYP19A1 (0.55) | CYP19A1KMT2AMAPTGAANFKB1 | |
| SCHEMBL17898386 | 0.85 | CYP19A1 (0.84) | CYP19A1MEN1KMT2AMAPTGAA | |
| SCHEMBL17536646 | 0.84 | CYP19A1 (0.74) | CYP19A1MEN1KMT2AMAPTGAA | |
| SCHEMBL23440024 | 0.83 | CYP19A1 (0.67) | CYP19A1MEN1KMT2AMAPTGAA | |
| SCHEMBL30969937 | 0.83 | CYP19A1 (0.67) | CYP19A1MEN1KMT2AMAPTGAA | |
| SCHEMBL26298767 | 0.78 | NFKB1 (0.60) | CYP19A1MEN1KMT2AMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2994460-B1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | UNIV INDIANA RES & TECH CORP (US) | 2024-12-04 | — | — | EP | disclosed |
| US-11707445-B2 | Composition for blocking angiogenesis | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2023-07-25 | — | — | US | disclosed |
| US-11707445-B2 | Composition for blocking angiogenesis | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2023-07-25 | — | — | US | disclosed |
| US-20210228538-A1 | COMPOSITION FOR BLOCKING ANGIOGENESIS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2021-07-29 | — | — | US | disclosed |
| US-10738024-B2 | Compounds for treatment of angiogenesis-mediated diseases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2020-08-11 | — | — | US | disclosed |
| US-10738024-B2 | Compounds for treatment of angiogenesis-mediated diseases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2020-08-11 | — | — | US | disclosed |
| US-10238627-B2 | Compounds for treatment of angiogenesis-mediated diseases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-03-26 | — | — | US | disclosed |
| US-10238627-B2 | Compounds for treatment of angiogenesis-mediated diseases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180177758-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2018-06-28 | — | — | US | disclosed |
| US-20180177758-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2018-06-28 | — | — | US | disclosed |
| US-20180177758-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2018-06-28 | — | — | US | disclosed |
| WO-2017091473-A1 | COMPOSITION FOR BLOCKING ANGIOGENESIS | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2017-06-01 | — | — | WO | disclosed |
| US-20160060241-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | GACHON UNIVERSITY OF INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2016-03-03 | — | — | US | disclosed |
| US-20160060241-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | GACHON UNIVERSITY OF INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2016-03-03 | — | — | US | disclosed |
| US-20160060241-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | GACHON UNIVERSITY OF INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11707445-B2 | Composition for blocking angiogenesis | FLT4, KDR, VEGFA | CYP19A1 1429/4885MEN1 4121/4885KMT2A 4719/4885 |
| US-10738024-B2 | Compounds for treatment of angiogenesis-mediated diseases | KDR, TEK, VEGFA | CYP19A1 260/4885MEN1 2818/4885KMT2A 4465/4885 |
| US-20210228538-A1 | COMPOSITION FOR BLOCKING ANGIOGENESIS | FLT4, KDR, VEGFA | CYP19A1 1429/4885MEN1 4121/4885KMT2A 4719/4885 |
| US-20180177758-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | KDR, TEK, VEGFA | CYP19A1 260/4885MEN1 2818/4885KMT2A 4465/4885 |
| US-20160060241-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | KDR, TEK, VEGFA | CYP19A1 260/4885MEN1 2818/4885KMT2A 4465/4885 |
| US-10238627-B2 | Compounds for treatment of angiogenesis-mediated diseases | KDR, TEK, VEGFA | CYP19A1 260/4885MEN1 2818/4885KMT2A 4465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.